AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06147414 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: A blood sample (50 ml) will be taken in care of prenatal diagnosis and 40 ml will be used for study.~The 40 mL of blood needed for the research will be collected on BCT tubes (4 tubes).~During the study, in centers, the plasma samples will be stored at room temperature and will be sent to the laboratory within 24 hours (no centrifugation in centers).~The plasma samples will be then temporarily stored at -80°C in each co-investigating laboratory under the supervision of lab supervisor until the analysis. cfDNA will be extracted from the whole plasma sample before each sequencing run and stored à +4°C until the cfDNA sequencing.
Study NCT06090890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Add 0.5mg QD orally and start using it within 48 hours after intervention.
Study NCT06629207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT with 18-FDG
Description: FDG-PET scans will be acquired in a Siemens Biograph Vision Quadra PET/CT (Siemens, Germany) at 30-minute post-injection of approximately 80 MBq 18F-FDG. The duration of the acquisition is 20 minutes. The PET images will be reconstructed with the vendor's time of flight (TOF) point-spread-function (PSF) algorithm, following corrections for randoms, scatter, and decay. Attenuation correction will be performed first using low-dose CT.
Study NCT06629207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPECT : 123 I-FP-CIT (DATSCAN)
Description: DaT-Scans will be acquired in a GE Discovery NM/CT 670 Pro™. After injection of approximately 110 MBq 123I-FP-CIT, images will be acquired within 4 h post-injection. The duration of the acquisition is 35 minutes.
Study NCT06090890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 0.5mg/kg QD orally and the dosage was reduced at a rate of 5mg/d per month until 5-10mg/d, maintained for 1 year after PCI.
Study NCT06090890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Patients who have re-implanted DES should receive aspirin for at least 1 year after intervention; Patients who have underwent DEB expansion should apply aspirin for at least 3 months after intervention.
Study NCT06090890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Patients who have re-implanted DES should receive aspirin for at least 1 year after intervention; Patients who have underwent DEB expansion should apply aspirin for at least 3 months after intervention.
Study NCT06090890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Y12 Receptor Antagonist
Description: Patients who have re-implanted DES should receive 1 P2Y12 receptor antagonist for at least 1 year after intervention; Patients who have underwent DEB expansion should apply the P2Y12 receptor antagonist for at least 3 months after intervention.
Study NCT06090890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P2Y12 Receptor Antagonist
Description: Patients who have re-implanted DES should receive 1 P2Y12 receptor antagonist for at least 1 year after intervention; Patients who have underwent DEB expansion should apply the P2Y12 receptor antagonist for at least 3 months after intervention.
Study NCT06090890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid-lowering drug
Description: Formulate the lipid-lowering drug regimen with LDL-C\<1.4mmol/L as the target on the basis of moderate intensity or above statins.
Study NCT06629207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI examination to exclude structural brain anomalies.
Study NCT06681571 — intervention group
Intervention type: OTHER
Intervention: TAP Block
Description: TAP block will be performed immediately after the induction of anesthesia, under ultrasond guidence.
Study NCT06681571 — intervention group
Intervention type: OTHER
Intervention: RSB
Description: Rectus Sheath block will be performed immediately after the induction of anesthesia, under Ultrasond guidence.
Study NCT06632691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality headset
Description: Use of a virtual reality headset during rectosigmoidoscopy
Study NCT06157918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA1813 oral solution (2.0g:25mg)
Description: SYHA1813 oral solution, 25mg, oral
Study NCT06157918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA1813 oral solution (20ml:200mg)
Description: SYHA1813 oral solution, 25mg, oral
Study NCT05005910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Vonoprazan 20 mg oral every 12 hours (total 72 hours)
Study NCT05005910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPIs IV infusion
Description: Pantoprazole 80 mg IV loading then 8 mg/hr
Study NCT06090890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipid-lowering drug
Description: Formulate the lipid-lowering drug regimen with LDL-C\<1.4mmol/L as the target on the basis of moderate intensity or above statins.
Study NCT05418985 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly reminder message about breast self-exam.
Description: Monthly reminder message about breast self-exam.
Study NCT05122351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine infiltration at the Quadratus Lumborum muscle Versus Paracetamol injection as analgesia in post operative Open Inguinal Hernia surgeries
Description: Comparative Study Between The Efficacy Of Quadratus Lumborum Block VS Conventional Analgesia In Patients Undergoing Open Inguinal Hernia Surgical Repair
Study NCT05207254 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonic test
Description: Ultrasonic test to the patient's head, neck and jaw area.
Study NCT05615779 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Randomized pectin diet
Description: UC and healthy control participants randomized to receive recommendations provided by a dietician increasing consumption of foods high in pectin
Study NCT05615779 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Randomized B-fructan diet
Description: UC and healthy control participants randomized to receive recommendations provided by a dietician increasing consumption of foods high in B-fructan
Study NCT05615779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized pectin diet
Description: UC and healthy control participants to receive recommendations provided by a dietician increasing consumption of foods high in pectin based on personal host (biopsy) and microbe (stool) response at baseline
Study NCT05615779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized B-fructan diet
Description: UC and healthy control participants to receive recommendations provided by a dietician increasing consumption of foods high in B-fructan based on personal host (biopsy) and microbe (stool) response at baseline
Study NCT04796545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SING IMT(TM) System, model NG SI IMT 3X
Description: The SING IMT 3X implant is a visual prosthetic implantable device, which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with bilateral, end-stage age-related macular degeneration.
Study NCT05744713 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Observational
Study NCT06064266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plant-based mild ketogenic controlled diet
Description: Plant-based mild ketogenic diet (10-20EN% carbohydrates, 10-20EN% protein, and 60-70EN% fat), consisting of a daily breakfast, lunch, dinner, and snacks.
Study NCT06064266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-fat shake
Description: The high-fat shake consists of unsweetened almond milk, sunflower oil, and plant sterols, resulting in a shake containing 885 kcal (1.5g protein, 97.3g fat, and 0.8g sugar).
Study NCT05544812 — intervention group
Intervention type: DRUG
Intervention: Sintilimab ，bevcizumab/cetuximab，XELOX
Description: Patients in this group had previously received the following treatment regimens:~Oxaliplatin :130 mg/m2, D1, Q3W; Capecitabine :1000mg/m2, bid q2w Sintilimab for injection :200mg, D1, Q3W Bevacizumab :7.5mg/kg, D1, Q3W or cetuximab :500 mg/m, D1, Q2W
Study NCT04937855 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT06560190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orthopaedic Manual Physical Therapy
Description: Individualized Treatment
Study NCT05562388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somnodent Classic
Description: The efficacy of the device will be evaluated in regards to the response of nocturia. Once patients report an average of voiding per night of less than 2 in the preceding 2 weeks of the follow up they will be classified as responders in term of nocturia and will be evaluated with a second sleep study. Efficacy of MAD will be assessed by comparing the apnea hypopnea index (AHI) values of pre and post sleep study with MAD, and they will be classified as responders if they have 50% improvement in AHI.
Study NCT05299320 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuromuscular fatigue and postural sway evaluation
Description: Neuromuscular fatigue will be established by using the Excalibur Sport Ergometer device and the Wingate Anaerobic Strength Test. Postural sway will be evaluated with Cyst Force Plate Balance device. This device is a precision device that provides objective measurable data.
Study NCT04729439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Homework Organization and Planning Skills (HOPS) Intervention
Description: A behavioral/organizational skills intervention focused on improving adolescents' homework, organization, and planning skills
Study NCT04729439 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Homework Organization and Planning Skills (HOPS) Intervention
Description: A behavioral/organizational skills intervention focused on improving adolescents' homework, organization, and planning skills
Study NCT04729439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Health Application (Online Platform) for Encouraging Skills Practice
Description: This online platform can be used on participants' personal devices including laptops, phones, tablets, or other computers and is designed to encourage adolescent's skills practice, monitor and reward treatment progress, and optimize motivation in treatment
Study NCT06438731 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BREAST MILK
Description: The preterm will be monitored for 5 minutes before birth, during the procedure cycle, and then by camera recording for 5 minutes
Study NCT06438731 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: KNITTED OCTOPUS
Description: The preterm will be monitored for 5 minutes before birth, during the procedure cycle, and then by camera recording for 5 minutes
Study NCT06101420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Venoprazan 20mg twice daily,clarithromycin 500mg twice daily,amoxycillin 1 gm twice daily,esomeprazole 20mg twice daily,levofloxacin 500mg a single tablet daily,doxycicline 100mg a single capsule daily and nitazoxanide 500mg twice daily
Study NCT06101420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan
Description: Venoprazan 20mg twice daily,clarithromycin 500mg twice daily,amoxycillin 1 gm twice daily,esomeprazole 20mg twice daily,levofloxacin 500mg a single tablet daily,doxycicline 100mg a single capsule daily and nitazoxanide 500mg twice daily
Study NCT05006248 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional robotic continuous passive movement training
Description: The participants will be single-blinded and wear the M1 robotic device on their affected/weaker foot, and complete up to 30 minutes of continuous passive movement per training session. The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session.
Study NCT05006248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual Feedback
Description: The participants will be single-blinded and wear the M1 robotic device in transparency mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session. The transparency mode of the robotic device compensates for its weight and friction so that the participant does not feel weight while moving the device.
Study NCT05006248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Haptic and Visual Feedback
Description: The participants will be single-blinded and wear the M1 robotic device in assistance mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session. The assistance mode of the robotic device applies assistive/resistive torque based on muscle activity.
Study NCT04642976 — intervention group
Intervention type: DEVICE
Intervention: Ganglionated Plexi mapping and ablation using Natus Cortical Stimulator and standard ablation catheters
Description: Ganglionated plexi will be mapped using high frequency stimulation with standard ablation catheters attached to a Natus Cortical Stimulator for high frequency stimulation. Vagal innervation to the heart will be assessed with non-invasive Parasym tragal stimulation.
Study NCT06288893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHEN211 Tablets
Description: SHEN211 tablets, participants will receive 330 mg (3 tablets) QD (once a day) on Day 1 and 110 mg (1 tablet) SHEN211 tablets QD orally on Days 2-5.
Study NCT06288893 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for SHEN211 Tablets
Description: Placebo tablets, participants will receive 3 tablets QD (once daily) on Day 1 and 1 tablet QD orally on Days 2-5
Study NCT06434298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choose to Move
Description: As described under study arm description
Study NCT04771312 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile app information-only intervention
Description: Mobile app intervention. Participants view information regarding PrEP that address beliefs and barriers surrounding adoption and uptake. Participants can respond to daily questions in a diary. Participants can also use a locator tool to find where PrEP can be found near them.
Study NCT04771312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile app social support network intervention
Description: Mobile app intervention. Participants view information regarding PrEP that address beliefs and barriers surrounding adoption and uptake. Participants are shown an online chatting tool where they can discuss with each other and answer daily questions. Participants can also use a locator tool to find where PrEP can be found near them.
Study NCT04781504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: intervention groups will complete supervised virtual exercise sessions for 12 weeks using the platform preferred by the patient (Zoom care, Zoom business, Google duo, google meet, FaceTime, join.me, WhatsApp Call, etc). The appointment will be scheduled and conducted 2 days per week. The first class will be conducted on-site to teach the patient how to take vitals and to do an in-person exercise session
Study NCT04984200 — intervention group
Intervention type: PROCEDURE
Intervention: Retinal imaging
Description: Subjects will undergo retinal imaging before and/or after administration of mydriatic agent
Study NCT04984200 — intervention group
Intervention type: DRUG
Intervention: Mydriatic Agent
Description: Subjects will be administered mydriatic medication to dilate their pupils.
Study NCT05860985 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ZEISS disposable
Description: a comparison will be done between the present lenses used (reusable RESIGHT lenses and disposable Vitreq contact lens) and the new disposable RESIGHT lenses.
Study NCT06068621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor
Description: 1. Azacytidine (75 mg/m2/day, days 1 to 7).~2. Cytarabine (75-100 mg/m2 bid, days 1 to 5).~3. Aclacinomycin(20 mg/day, days 1,3,5).~4. Chidamide (30 mg/day , days 1,4,8,11).~5. Venetoclax (400 mg/day, days 1 to 14,Combined with posaconazole reduced to 100 mg/day,Combined with voriconazole reduced to 200 mg/day ).~6. Granulocyte colony-stimulating factor (300 μg/day, day 0 until agranulocytosis recovery)
Study NCT06068621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3+7
Description: IA regimen:~1. Idarubicin (8-10 mg/m2) for 3 days .~2. Cytarabine (75-100mg/m2, every 12 hrs) for 7 days.~DA regimen:~1. Daunorubicin(60 mg/m2) for 3 days.~2. Cytarabine (75-100mg/m2, every 12 hrs) for 7 days.
Study NCT05321602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03010 156 mg treatment group, deltoid
Description: LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
Study NCT05321602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03010 156 mg treatment group, gluteal
Description: LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
Study NCT05321602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03010 351 mg treatment group, deltoid
Description: LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
Study NCT05321602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03010 351 mg treatment group, gluteal
Description: LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
Study NCT05665283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ensartinib Hydrochloride
Description: oral ALK inhibitor
Study NCT05809700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Freshly manufactured 35 kDa hyaluronan fragment
Description: This mixture of high molecular weight HA and hyaluronidase containing 100 mg of HA was locally injected at the pain point or where the nerve trunk innervates the pain point. Then, the pain scale (NPRS) was used to evaluate pain, and the pain relief of patients before and after treatment was recorded.~Each time, according to the amount of high molecular weight HA containing 100 mg HA and hyaluronidase mixture, the pain point area and pain point area of the nerve trunk innervation of the local multipoint injection. Then, the pain scale was used to evaluate pain, and the pain relief of patients before and after treatment was recorded.
Study NCT05272605 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1 + MF59)
Description: Single booster dose in healthy adults previously vaccinated with two doses of CominartyTM (BNT162b2 \[mRNA\]) or VaxzevriaTM (ChAdOx1-S) COVID-19 and a third booster dose of either ComirnatyTM or SpikevaxTM vaccines.
Study NCT05272605 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 beta variant RBD mRNA vaccine
Description: Single booster dose in healthy adults previously vaccinated with two doses of CominartyTM (BNT162b2 \[mRNA\]) or VaxzevriaTM (ChAdOx1-S) COVID-19 and a third booster dose of either ComirnatyTM or SpikevaxTM vaccines.
Study NCT05272605 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo comparator
Study NCT05600751 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiosurgery of ganglion stellatum
Description: Patients will undergo radiosurgery of ganglion stellatum (left one or both)
Study NCT06334796 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Assistant
Description: Stage 1 focused on safety, using only medical information from clinical records for the virtual assistant. In Stage 2, which evaluated accuracy, participants interacted with the virtual assistant post-medical stabilization. Additionally, participants also provided initial symptom details for Chat-GPT input. Nine neurologists specializing in emergency participated in the study. In Stage 1, they assessed the virtual assistant's performance using clinical history information. In Stage 2, they analyzed the results from participant interactions with the assistant and performed a comparative evaluation of Chat-GPT. The virtual assistant functioned as a chatbot on WhatsApp and Telegram, using Spanish and incorporating advanced algorithms, decision trees, and large language models for interaction. For comparison, we utilized Chat-GPT versions 3.5 and 4, employing two prompt types in natural Spanish: one incorporating clinical record data and the other based on participant narratives.